ALT 766
Alternative Names: PTBLatest Information Update: 25 Sep 2021
At a glance
- Originator Alteon
- Class Antihyperglycaemics
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 08 May 2001 Discontinued-Preclinical for Diabetic complications in USA (Unknown route)
- 26 Feb 2001 Profile reviewed but no significant changes made
- 03 Aug 1998 No-Development-Reported for Diabetic complications in USA (Unknown route)